George Malietzis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
George Malietzis has a total of 388 co-authors. Here are the top co-authors by number of shared publications:
- John Taylor Jenkins
St Marks Hospital, Complex Cancer Clinic , London
8 shared publications - Alan Askari
Bedfordshire Hospitals NHS Foundation Trust, Luton, UK
5 shared publications - Omer Aziz
Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
5 shared publications - Gregory C. Makris
Bayer AG London UK
4 shared publications - Gui Han Lee
Department of Colorectal Surgery, St Mark's Hospital, London, UK
4 shared publications - David Bernardo
Mucosal Immunology Lab, Instituto de Biología y Genética Molecular (IBGM, Universidad de Valladolid-CISC), Valladolid, Spain
3 shared publications
Latest Publications
- Open Access
- 23 February 2022
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 6 (1)
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study
Perioperative FLOT (fluorouracil plus leucovorin, oxaliplatin, and docetaxel) chemotherapy is a recent regimen used to treat resectable oesophagogastric (OG) adenocarcinoma, associated with improved overall survival versus earlier chemotherapy strategies. This study compared short-term perioperative morbidity in a large tertiary centre series of FLOT to a matched cohort receiving ECX/ECF (epirubicin, cisplatin, capecitabine (X) or 5-fluorouracil (F)). Consecutive patients completing four perioperative cycles of FLOT and proceeding to surgery with resectable OG adenocarcinoma were included. This was matched to patients from a historic ECX/ECF cohort from the same institution. A propensity score was calculated, and a secondary analysis using a propensity-matched group performed. Cohorts were matched by tumour location and operations performed. In total there were 129 (64.5 per cent) oesophageal and 71 (35.5 per cent) gastric resections (FLOT 57 oesophageal, 43 gastric; ECF/ECX 64 oesophageal, 36 gastric). The median length of stay after surgery was 12 days in the FLOT group versus 15 in ECF/ECX (P = 0.035). There were no significant differences in overall perioperative complications and, specifically, no difference in OG anastomotic leaks, analysed by site (gastric (FLOT 0/79 (0 per cent) versus ECX 2/79 (2.5 per cent); P = 0.123), oesophageal (FLOT 4/121 (3.3 per cent) versus ECX 5/121 (4.1 per cent); P = 0.868) or type of surgery (open FLOT 1/121 (0.8 per cent) versus ECX 3/121 (2.5 per cent); P = 0.368; minimally invasive (FLOT 3/121 (2.5 per cent) versus ECX 2/121 (1.7 per cent); P = 0.555)). There was no statistical difference in leak-related return to theatre, 30-day (FLOT 0 (0 per cent) versus ECX 3/100 (3.0 per cent); P = 0.081), or 90-day (FLOT 0 (0 per cent) versus ECX 2/100 (2.0 per cent); P = 0.155) mortality. In terms of surgical complications, FLOT and ECX/ECF were equally safe in patients undergoing resection for OG adenocarcinoma.
- 23 February 2022
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 6 (1)
Open AccessEffect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study
Perioperative FLOT (fluorouracil plus leucovorin, oxaliplatin, and docetaxel) chemotherapy is a recent regimen used to treat resectable oesophagogastric (OG) adenocarcinoma, associated with improved overall survival versus earlier chemotherapy strategies. This study compared short-term perioperative morbidity in a large tertiary centre series of FLOT to a matched cohort receiving ECX/ECF (epirubicin, cisplatin, capecitabine (X) or 5-fluorouracil (F)). Consecutive patients completing four perioperative cycles of FLOT and proceeding to surgery with resectable OG adenocarcinoma were included. This was matched to patients from a historic ECX/ECF cohort from the same institution. A propensity score was calculated, and a secondary analysis using a propensity-matched group performed. Cohorts were matched by tumour location and operations performed. In total there were 129 (64.5 per cent) oesophageal and 71 (35.5 per cent) gastric resections (FLOT 57 oesophageal, 43 gastric; ECF/ECX 64 oesophageal, 36 gastric). The median length of stay after surgery was 12 days in the FLOT group versus 15 in ECF/ECX (P = 0.035). There were no significant differences in overall perioperative complications and, specifically, no difference in OG anastomotic leaks, analysed by site (gastric (FLOT 0/79 (0 per cent) versus ECX 2/79 (2.5 per cent); P = 0.123), oesophageal (FLOT 4/121 (3.3 per cent) versus ECX 5/121 (4.1 per cent); P = 0.868) or type of surgery (open FLOT 1/121 (0.8 per cent) versus ECX 3/121 (2.5 per cent); P = 0.368; minimally invasive (FLOT 3/121 (2.5 per cent) versus ECX 2/121 (1.7 per cent); P = 0.555)). There was no statistical difference in leak-related return to theatre, 30-day (FLOT 0 (0 per cent) versus ECX 3/100 (3.0 per cent); P = 0.081), or 90-day (FLOT 0 (0 per cent) versus ECX 2/100 (2.0 per cent); P = 0.155) mortality. In terms of surgical complications, FLOT and ECX/ECF were equally safe in patients undergoing resection for OG adenocarcinoma.
- 1 March 2020
- Published by Elsevier in Clinical Nutrition
- Vol. 39 (3) , 829-836
Survival and CT defined sarcopenia in patients with intestinal failure on home parenteral support
- 1 March 2020
- Published by Elsevier in Clinical Nutrition
- Vol. 39 (3) , 829-836
Survival and CT defined sarcopenia in patients with intestinal failure on home parenteral support
- Open Access
OWE-020 Survival and CT defined sarcopenia in patients with intestinal failure on HPN
Introduction Sarcopenia is recognised in patients with intestinal failure (IF) and has been associated with poorer survival in several chronic diseases. CT can measure sarcopenia through a L3 skeletal muscle index (LSMI). We aim to evaluate the prevalence of sarcopenia in our IF population using LSMI, and evaluate the effect of home parenteral support (HPN) on LSMI and survival. Additionally, we aim to assess any association between LSMI, BMI and other anthropometric measurements. Methods IF patients on HPN treated at St Mark’s Hospital between 1/1/2006–1/10/2016 were identified from a prospectively maintained database. Patients were included if they were on HPN and had 2 CTs: the first ≤30 days before start of HPN (pre-HPN); the second ≥100 days from HPN start (post-HPN). Patient records were reviewed to obtain clinical and demographic information and date of death. Anthropometric measurements and BMI contemporaneous to CT scans were recorded. Results 64 patients met inclusion criteria (M:F 1:1). 83% of our cohort had LSMI below previously published thresholds for sarcopenia. Mean pre-HPN LSMI was 36.5±6.8 cm2/m2. Mean BMI pre-HPN was 22.1±4.8 kg/m2. Both BMI (pConclusions This study is the first to look at sarcopenia and survival using CT defined LSMI in the IF population. 83% of our cohort had a pre-HPN LSMI below previously published thresholds, yet we found no relationship between lower baseline LSMI and survival. This may reflect the heterogeneity of the prognoses of the IF population, or that parenteral nutrition itself affects survival. Our study showed that LSMI and BMI improved following HPN but demonstrated that other anthropometric measurements had poor correlation with LSMI and showed no significant improvement overall after HPN, confirming the known problems of inter-operator and patient variability of these measurements. Whilst we found significant correlation between LSMI and BMI, BMI significantly underestimated the presence and degree of sarcopenia. We have shown LSMI can provide an objective and reproducible measure of sarcopenia in IF. Future larger studies should be performed to evaluate associations with patient outcomes and utility in clinical decision making.
Open AccessOWE-020 Survival and CT defined sarcopenia in patients with intestinal failure on HPN
Introduction Sarcopenia is recognised in patients with intestinal failure (IF) and has been associated with poorer survival in several chronic diseases. CT can measure sarcopenia through a L3 skeletal muscle index (LSMI). We aim to evaluate the prevalence of sarcopenia in our IF population using LSMI, and evaluate the effect of home parenteral support (HPN) on LSMI and survival. Additionally, we aim to assess any association between LSMI, BMI and other anthropometric measurements. Methods IF patients on HPN treated at St Mark’s Hospital between 1/1/2006–1/10/2016 were identified from a prospectively maintained database. Patients were included if they were on HPN and had 2 CTs: the first ≤30 days before start of HPN (pre-HPN); the second ≥100 days from HPN start (post-HPN). Patient records were reviewed to obtain clinical and demographic information and date of death. Anthropometric measurements and BMI contemporaneous to CT scans were recorded. Results 64 patients met inclusion criteria (M:F 1:1). 83% of our cohort had LSMI below previously published thresholds for sarcopenia. Mean pre-HPN LSMI was 36.5±6.8 cm2/m2. Mean BMI pre-HPN was 22.1±4.8 kg/m2. Both BMI (pConclusions This study is the first to look at sarcopenia and survival using CT defined LSMI in the IF population. 83% of our cohort had a pre-HPN LSMI below previously published thresholds, yet we found no relationship between lower baseline LSMI and survival. This may reflect the heterogeneity of the prognoses of the IF population, or that parenteral nutrition itself affects survival. Our study showed that LSMI and BMI improved following HPN but demonstrated that other anthropometric measurements had poor correlation with LSMI and showed no significant improvement overall after HPN, confirming the known problems of inter-operator and patient variability of these measurements. Whilst we found significant correlation between LSMI and BMI, BMI significantly underestimated the presence and degree of sarcopenia. We have shown LSMI can provide an objective and reproducible measure of sarcopenia in IF. Future larger studies should be performed to evaluate associations with patient outcomes and utility in clinical decision making.
- Open Access
- 24 October 2017
- Published by Wiley in World Journal of Surgery
- Vol. 42 (4) , 937-949
“The Longest Way Round Is The Shortest Way Home”: An Overhaul of Surgical Ward Rounds
Background: Ward rounds, a keystone of hospital surgical practice, have recently been under the spotlight. Poor‐quality ward rounds can lead to a greater number of adverse events, thereby cascading to an increased financial strain on our already burdened healthcare systems. Faced with mounting pressures from both outside and inside health organizations, concerted efforts are required to restore it back into prominence where it can no longer take a backseat to the other duties of a surgeon.Methods: The nucleus of this narrative review is derived from an extensive literature search on surgical ward rounds.Results: In this review, we focus on the need for reforms, current characteristics of surgical ward rounds, obstacles encountered by competing interests and proposed solutions in delivery of effective ward rounds that can meet with newly laid guidelines.Conclusion: Ward rounds should be standardized and prioritized to improve patient care.
- 24 October 2017
- Published by Wiley in World Journal of Surgery
- Vol. 42 (4) , 937-949
Open Access“The Longest Way Round Is The Shortest Way Home”: An Overhaul of Surgical Ward Rounds
Background: Ward rounds, a keystone of hospital surgical practice, have recently been under the spotlight. Poor‐quality ward rounds can lead to a greater number of adverse events, thereby cascading to an increased financial strain on our already burdened healthcare systems. Faced with mounting pressures from both outside and inside health organizations, concerted efforts are required to restore it back into prominence where it can no longer take a backseat to the other duties of a surgeon.Methods: The nucleus of this narrative review is derived from an extensive literature search on surgical ward rounds.Results: In this review, we focus on the need for reforms, current characteristics of surgical ward rounds, obstacles encountered by competing interests and proposed solutions in delivery of effective ward rounds that can meet with newly laid guidelines.Conclusion: Ward rounds should be standardized and prioritized to improve patient care.
- 7 September 2017
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 46 (9) , 883-891
The body composition profile is associated with response to anti‐TNF therapy in Crohn's disease and may offer an alternative dosing paradigm
Summary: Background: Anti‐tumour necrosis factor (TNF)s form a major part of therapy in Crohn's disease and have a primary nonresponse rate of 10%‐30% and a secondary loss of response rate of 5% per year. Myopenia is prevalent in Crohn's disease and is measured using body composition analysis tools.Aim: To test the hypothesis that body composition can predict outcomes of anti‐TNF primary nonresponse and secondary loss of response.Methods: Between January 2007 and June 2012, 106 anti‐TNF naïve patients underwent anti‐TNF therapy for Crohn's disease with body composition parameters analysed using CT scans to estimate body fat‐free mass. The outcome measures were primary nonresponse and secondary loss of response. COX‐regression analysis was used with 3 year follow‐up data.Results: A total of 106 patients were included for analysis with 26 (24.5%) primary nonresponders and 29 (27.4%) with secondary loss of response to anti‐TNF therapy. Sex‐specific cut‐offs for muscle and fat were ascertained by stratification analysis. On univariate analysis, primary nonresponse was associated with low albumin (OR 0.94; 0.88‐0.99, P = .04) and presence of myopenia (OR 4.69; 1.83‐12.01, P = .001) when taking into account patient's medical therapy, severity of disease and body composition. On multivariate analysis, presence of myopenia was associated with primary nonresponse (OR 2.93; 1.28‐6.71, P = .01). Immunomodulator therapy was associated with decreased secondary loss of response (OR 0.48; 0.23‐0.98, P = .04). BMI was poorly correlated with lean body mass (r2 = 0.15, P = .54).Conclusions: In this cohort study, body composition profiles did not correlate well with BMI. Myopenia was associated with primary nonresponse with potential implications for dosing and serves as an explanation for pharmacokinetic failure.
- 7 September 2017
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 46 (9) , 883-891
The body composition profile is associated with response to anti‐TNF therapy in Crohn's disease and may offer an alternative dosing paradigm
Summary: Background: Anti‐tumour necrosis factor (TNF)s form a major part of therapy in Crohn's disease and have a primary nonresponse rate of 10%‐30% and a secondary loss of response rate of 5% per year. Myopenia is prevalent in Crohn's disease and is measured using body composition analysis tools.Aim: To test the hypothesis that body composition can predict outcomes of anti‐TNF primary nonresponse and secondary loss of response.Methods: Between January 2007 and June 2012, 106 anti‐TNF naïve patients underwent anti‐TNF therapy for Crohn's disease with body composition parameters analysed using CT scans to estimate body fat‐free mass. The outcome measures were primary nonresponse and secondary loss of response. COX‐regression analysis was used with 3 year follow‐up data.Results: A total of 106 patients were included for analysis with 26 (24.5%) primary nonresponders and 29 (27.4%) with secondary loss of response to anti‐TNF therapy. Sex‐specific cut‐offs for muscle and fat were ascertained by stratification analysis. On univariate analysis, primary nonresponse was associated with low albumin (OR 0.94; 0.88‐0.99, P = .04) and presence of myopenia (OR 4.69; 1.83‐12.01, P = .001) when taking into account patient's medical therapy, severity of disease and body composition. On multivariate analysis, presence of myopenia was associated with primary nonresponse (OR 2.93; 1.28‐6.71, P = .01). Immunomodulator therapy was associated with decreased secondary loss of response (OR 0.48; 0.23‐0.98, P = .04). BMI was poorly correlated with lean body mass (r2 = 0.15, P = .54).Conclusions: In this cohort study, body composition profiles did not correlate well with BMI. Myopenia was associated with primary nonresponse with potential implications for dosing and serves as an explanation for pharmacokinetic failure.
- 20 October 2016
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 103 (13) , 1783-1794
Network meta-analysis of protocol-driven care and laparoscopic surgery for colorectal cancer
Background: Laparoscopic approaches and standardized recovery protocols have reduced morbidity following colorectal cancer surgery. As the optimal regimen remains inconclusive, a network meta-analysis was undertaken of treatments for the development of postoperative complications and mortality. Methods: MEDLINE, Embase, trial registries and related reviews were searched for randomized trials comparing laparoscopic and open surgery within protocol-driven or conventional perioperative care for colorectal cancer resection, with complications as a defined endpoint. Relative odds ratios (ORs) for postoperative complications and mortality were estimated for aggregated data. Results: Forty trials reporting on 11 516 randomized patients were included with the network. Open surgery within conventional perioperative care was the index for comparison. The OR relating to complications was 0·77 (95 per cent c.i. 0·65 to 0·91) for laparoscopic surgery within conventional care, 0·69 (0·48 to 0·99) for open surgery within protocol-driven care, and 0·43 (0·28 to 0·67) for laparoscopic surgery within protocol-driven care. Sensitivity analyses excluding trials of low rectal cancer and those with a high risk of bias did not affect the treatment estimates. Meta-analyses demonstrated that mortality risk was unaffected by perioperative strategy. Conclusion: Laparoscopic surgery combined with protocol-driven care reduces colorectal cancer surgery complications, but not mortality. The reduction in complications with protocol-driven care is greater for open surgery than for laparoscopic approaches. Registration number: CRD42015017850 (https://www.crd.york.ac.uk/PROSPERO)
- 20 October 2016
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 103 (13) , 1783-1794
Network meta-analysis of protocol-driven care and laparoscopic surgery for colorectal cancer
Background: Laparoscopic approaches and standardized recovery protocols have reduced morbidity following colorectal cancer surgery. As the optimal regimen remains inconclusive, a network meta-analysis was undertaken of treatments for the development of postoperative complications and mortality. Methods: MEDLINE, Embase, trial registries and related reviews were searched for randomized trials comparing laparoscopic and open surgery within protocol-driven or conventional perioperative care for colorectal cancer resection, with complications as a defined endpoint. Relative odds ratios (ORs) for postoperative complications and mortality were estimated for aggregated data. Results: Forty trials reporting on 11 516 randomized patients were included with the network. Open surgery within conventional perioperative care was the index for comparison. The OR relating to complications was 0·77 (95 per cent c.i. 0·65 to 0·91) for laparoscopic surgery within conventional care, 0·69 (0·48 to 0·99) for open surgery within protocol-driven care, and 0·43 (0·28 to 0·67) for laparoscopic surgery within protocol-driven care. Sensitivity analyses excluding trials of low rectal cancer and those with a high risk of bias did not affect the treatment estimates. Meta-analyses demonstrated that mortality risk was unaffected by perioperative strategy. Conclusion: Laparoscopic surgery combined with protocol-driven care reduces colorectal cancer surgery complications, but not mortality. The reduction in complications with protocol-driven care is greater for open surgery than for laparoscopic approaches. Registration number: CRD42015017850 (https://www.crd.york.ac.uk/PROSPERO)
- Open Access
- 11 May 2016
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 103 (8) , 1076-1083
Outcomes following laparoscopic rectal cancer resection by supervised trainees
The aim was to evaluate the applicability of laparoscopic surgery in the treatment of primary rectal cancer in a training unit. A cohort analysis was undertaken of consecutive patients undergoing elective surgery for primary rectal cancer over a 7-year interval. Data on patient and operative details, and short-term clinicopathological outcomes were collected prospectively and analysed on an intention-to-treat basis. A total of 306 patients (213 men, 69·6 per cent) of median (i.q.r.) age 67 (58–73) years with a median body mass index of 26·6 (23·9–29·9) kg/m2 underwent surgery. Median tumour height was 8 (6–11) cm from the anal verge, and 46 patients (15·0 per cent) received neoadjuvant radiotherapy. Seven patients (2·3 per cent) were considered unsuitable for laparoscopic surgery and underwent open resection; 299 patients (97·7 per cent) were suitable for laparoscopic surgery, but eight were randomized to open surgery as part of an ongoing trial. Some 291 patients (95·1 per cent) underwent a laparoscopic procedure, with conversion required in 29 (10·0 per cent). Surgery was partially or completely performed by trainees in 72·4 per cent of National Health Service patients (184 of 254), whereas private patients underwent surgery primarily by consultants. Median postoperative length of stay for all patients was 6 days and the positive circumferential resection margin rate was 4·9 per cent (15 of 306). Supervised trainees can perform routine laparoscopic rectal cancer resection.
- 11 May 2016
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 103 (8) , 1076-1083
Open AccessOutcomes following laparoscopic rectal cancer resection by supervised trainees
The aim was to evaluate the applicability of laparoscopic surgery in the treatment of primary rectal cancer in a training unit. A cohort analysis was undertaken of consecutive patients undergoing elective surgery for primary rectal cancer over a 7-year interval. Data on patient and operative details, and short-term clinicopathological outcomes were collected prospectively and analysed on an intention-to-treat basis. A total of 306 patients (213 men, 69·6 per cent) of median (i.q.r.) age 67 (58–73) years with a median body mass index of 26·6 (23·9–29·9) kg/m2 underwent surgery. Median tumour height was 8 (6–11) cm from the anal verge, and 46 patients (15·0 per cent) received neoadjuvant radiotherapy. Seven patients (2·3 per cent) were considered unsuitable for laparoscopic surgery and underwent open resection; 299 patients (97·7 per cent) were suitable for laparoscopic surgery, but eight were randomized to open surgery as part of an ongoing trial. Some 291 patients (95·1 per cent) underwent a laparoscopic procedure, with conversion required in 29 (10·0 per cent). Surgery was partially or completely performed by trainees in 72·4 per cent of National Health Service patients (184 of 254), whereas private patients underwent surgery primarily by consultants. Median postoperative length of stay for all patients was 6 days and the positive circumferential resection margin rate was 4·9 per cent (15 of 306). Supervised trainees can perform routine laparoscopic rectal cancer resection.
- Open Access
- 18 March 2016
- Published by Springer Nature in European Radiology
- Vol. 27 (1) , 51-60
CT colonography for surveillance of patients with colorectal cancer: Systematic review and meta-analysis of diagnostic efficacy
To review primary research evidence investigating performance of CT colonography for colorectal cancer surveillance. The financial impact of using CT colonography for surveillance was also estimated. We identified primary studies of CT colonography for surveillance of colorectal cancer patients. A summary ROC curve was constructed. Inter-study heterogeneity was explored using the I2 value. Financial impact was estimated for a theoretical cohort of patients, based on Cancer Research UK statistics. Seven studies provided data on 880 patients. Five of seven studies (765 patients) were included for qualitative analysis. Sensitivity of CT colonography for detection of anastomotic recurrence was 95 % (95 % CI 62 - 100), specificity 100 % (95 % CI 75 - 100) and sensitivity for metachronous cancers was 100 %. No statistical heterogeneity was detected (I2 = 0 %). We estimated that CT colonography as a 'single test' alternative to colonoscopy and standard CT for surveillance would potentially save €20,785,232 (£14,803,404) for an annual cohort of UK patients. CT colonography compares favourably to colonoscopy for detection of anastomotic recurrence and metachronous colorectal cancer, and appears financially beneficial. These findings should be considered alongside limitations of small patient numbers and high clinical heterogeneity between studies. • CT colonography compares favourably to colonoscopy/standard CT for colorectal cancer surveillance. • CT colonography offers single-test luminal, serosal and extra-colonic assessment. • CT colonography is a potentially cost-saving alternative to standard surveillance protocols.
- 18 March 2016
- Published by Springer Nature in European Radiology
- Vol. 27 (1) , 51-60
Open AccessCT colonography for surveillance of patients with colorectal cancer: Systematic review and meta-analysis of diagnostic efficacy
To review primary research evidence investigating performance of CT colonography for colorectal cancer surveillance. The financial impact of using CT colonography for surveillance was also estimated. We identified primary studies of CT colonography for surveillance of colorectal cancer patients. A summary ROC curve was constructed. Inter-study heterogeneity was explored using the I2 value. Financial impact was estimated for a theoretical cohort of patients, based on Cancer Research UK statistics. Seven studies provided data on 880 patients. Five of seven studies (765 patients) were included for qualitative analysis. Sensitivity of CT colonography for detection of anastomotic recurrence was 95 % (95 % CI 62 - 100), specificity 100 % (95 % CI 75 - 100) and sensitivity for metachronous cancers was 100 %. No statistical heterogeneity was detected (I2 = 0 %). We estimated that CT colonography as a 'single test' alternative to colonoscopy and standard CT for surveillance would potentially save €20,785,232 (£14,803,404) for an annual cohort of UK patients. CT colonography compares favourably to colonoscopy for detection of anastomotic recurrence and metachronous colorectal cancer, and appears financially beneficial. These findings should be considered alongside limitations of small patient numbers and high clinical heterogeneity between studies. • CT colonography compares favourably to colonoscopy/standard CT for colorectal cancer surveillance. • CT colonography offers single-test luminal, serosal and extra-colonic assessment. • CT colonography is a potentially cost-saving alternative to standard surveillance protocols.